Company Overview and News


Add SGMO
to your dashboard

Headline News

Sangamo Jumps on Newest Pfizer Collaboration

2018-01-03 247wallst
Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer Inc. (NYSE: PFE) for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). (35-1)

Biotech Bonanza: Biotech Stocks To Keep Shining In 2018

2017-12-19 seekingalpha
On a relative basis, Biotechs represent a good opportunity as the sector remains ~20% below its all-time high. (617-5)

Baker Bros Advisors LP Upped By $4.67 Million Its Achaogen (AKAO) Position; Fti Consulting (FCN) Has 1 Sentiment - Herald KS

2017-12-19 heraldks
FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company has market cap of $1.60 billion. The companyÂ’s Corporate Finance & Restructuring segment provides business transformation, turnaround and restructuring, interim management, transaction, valuation and financial advisory, dispute advisory, and tax services, as well as mergers and acquisitions , and M & A integration services. (112-4)

Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases

2017-12-07 seekingalpha
One of the four trials Sangamo has in the clinical is SB-525.  Pfizer agreed to potential milestone payments of $475 million plus royalties to collaborate with them on this product. (25-0)

Biotech Forum Daily Digest: What Now For Recro Pharma?

2017-11-27 seekingalpha
The main biotech indices posted small gains in the holiday shortened trading week just before Thanksgiving. (332-0)

Bioverativ: A Rare Pearl In Biotech

2017-11-23 seekingalpha
Spin-offs have a history of outperformance. Alcoa (NYSE: AA) is a good example. Another example is Bioverativ (NASDAQ: BIVV), the Hemophilia-business unit that was spun-off from Biogen earlier this year. (115-1)

The Small Cap Rush!

2017-10-10 seekingalpha
The enduring power of small cap relative outperformance presents a compelling investment case for long-term investors. (267-2)

Best Performing Stocks YTD Through Q3 2017

2017-10-03 seekingalpha
Below is a list of the 40 best-performing Russell 3,000 stocks on a year-to-date basis through the third quarter of 2017. You'll notice that a bulk of the names on the list of biggest winners are from the Biotech space. Dynavax Tech (NASDAQ:DVAX) ranks first with a YTD gain of 444%. Straight Path (NYSEMKT:STRP) ranks second at +432.79% but it's in the process of getting acquired after a bidding war for the company's valuable spectrum. (179-9)

Move Over Yellen! It's Tax Cut Time!

2017-09-29 seekingalpha
The health care repeals effort fizzle out clearing the desk for Congress to focus on tax cuts. (590-0)

Daily Technical Summary Reports on Biotech Stocks -- Gilead Sciences, Kite Pharma, Novavax, and Sangamo Therapeutics

2017-09-29 prnewswire
If you want a Stock Review on GILD, KITE, NVAX, or SGMO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com navigates the Biotech space, which is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include medical, agricultural, environmental, and industrial. (208-3)

Will The Federal Reserve Send The Market Higher?

2017-09-19 seekingalpha
It will be prudent to push out the next rate increase to 2018, particularly as there may be unanticipated risks of a balance sheet drawdown, and the linkage between unemployment rate and inflation has weakened. (409-0)

3 Biotech Stocks That Have Already Quadrupled in 2017

2017-09-13 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (4-4)

Sangamo Therapeutics: The Breakthrough In Gene Therapy

2017-08-17 seekingalpha
SGMO is initiating its execution of commercially viable ZFN drugs, facilitating future pharmaceutical solutions and a financial instrument with which to hedge CRISPR.

This Technology Could Make You Rich -- and Change the World As We Know It

2017-08-13 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-3)

Looking Beyond Factors In Hemophilia

2017-08-10 seekingalpha
The hemophilia market is set for a shake-up - in the near term with Roche's (OTCQX:RHHBY) bispecific antibody emicizumab and in the longer term with even more convenient, longer-lasting options. These projects could put a squeeze on the makers of traditional factor-replacement products, with Shire (NASDAQ:SHPG) having the most to lose. (0-1)

CUSIP: 800677106